Macrophage inflammatory markers are associated with subclinical carotid artery disease in women with human immunodeficiency virus or hepatitis C virus infection

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 34, Issue 5, 2014, Pages 1085-1092

  Shaked, Iftach ^a   Hanna, David B ^a   Gleißner, Christian ^h   Marsh, Brenda ⁱ   Plants, Jill ^b   Tracy, Daniel ^a   Anastos, Kathryn ^a   Cohen, Mardge ^b   Golub, Elizabeth T ^c   Karim, Roksana ^a   Lazar, Jason ^e   Prasad, Vinayaka ^a   Tien, Phyllis C ^g   Young, Mary A ^d   Landay, Alan L ^b   Kaplan, Robert C ^f   Ley, Klaus ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b RUSH UNIVERSITY   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^e SUNY DOWNSTATE MEDICAL CENTER   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF HEIDELBERG   (Germany)

ⁱ UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

acquired immunodeficiency syndrome; atherosclerosis; immune system; risk factors; women

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD14 ANTIGEN; GALECTIN 3; GALECTIN 3 BINDING PROTEIN; UNCLASSIFIED DRUG;

ARTERIAL WALL THICKNESS; ARTERY COMPLIANCE; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD LEVEL; CAROTID ARTERY DISEASE; CD4 LYMPHOCYTE COUNT; CELL DIFFERENTIATION; COMMON CAROTID ARTERY; DISEASE ASSOCIATION; DISEASE MARKER; ETHNICITY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IN VITRO STUDY; INFLAMMATION; MACROPHAGE; PREDICTIVE VALUE; PRIORITY JOURNAL; RACE; RISK FACTOR; SMOKING; ULTRASOUND;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ATHEROSCLEROSIS; IMMUNE SYSTEM; RISK FACTORS; WOMEN;

ADULT; ANTIGENS, CD; ANTIGENS, CD14; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTIGENS, NEOPLASM; ASYMPTOMATIC DISEASES; BIOLOGICAL MARKERS; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CARRIER PROTEINS; COINFECTION; CROSS-SECTIONAL STUDIES; FEMALE; GLYCOPROTEINS; HEPATITIS C; HIV INFECTIONS; HUMANS; INFLAMMATION MEDIATORS; MACROPHAGES; MIDDLE AGED; RECEPTORS, CELL SURFACE; RISK FACTORS; SEX FACTORS; SMOKING; TUMOR MARKERS, BIOLOGICAL; VASCULAR STIFFNESS;

EID: 84899658859     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.113.303153     Document Type: Article

References (37)

1. Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective. Lancet. ePub: September 29, 2013.
2. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32:2045-2051.
3. Libby P, Ridker PM. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med. 2004;116 Suppl 6A:9S-16S
4. Koltsova EK, Garcia Z, Chodaczek G, Landau M, McArdle S, Scott SR, von Vietinghoff S, Galkina E, Miller YI, Acton ST, Ley K. Dynamic T cell-APC interactions sustain chronic inflammation in atherosclerosis. J Clin Invest. 2012;122:3114-3126.
5. Stöger JL, Gijbels MJ, van der Velden S, Manca M, van der Loos CM, Biessen EA, Daemen MJ, Lutgens E, de Winther MP. Distribution of macrophage polarization markers in human atherosclerosis. Atherosclerosis. 2012;225:461-468.
6. Kadl A, Meher AK, Sharma PR, Lee MY, Doran AC, Johnstone SR, Elliott MR, Gruber F, Han J, Chen W, Kensler T, Ravichandran KS, Isakson BE, Wamhoff BR, Leitinger N. Identification of a novel macrophage phenotype that develops in response to atherogenic phospholipids via Nrf2. Circ Res. 2010;107:737-746.
7. Hanna RN, Shaked I, Hubbeling HG, Punt JA, Wu R, Herrley E, Zaugg C, Pei H, Geissmann F, Ley K, Hedrick CC. NR4A1 (Nur77) deletion polarizes macrophages toward an inflammatory phenotype and increases atherosclerosis. Circ Res. 2012;110:416-427.
8. Leitinger N, Schulman IG. Phenotypic polarization of macrophages in atherosclerosis. Arterioscler Thromb Vasc Biol. 2013;33:1120-1126.
9. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol. 2000;164:6166-6173.
10. Wolfs IM, Donners MM, de Winther MP. Differentiation factors and cytokines in the atherosclerotic plaque micro-environment as a trigger for macrophage polarisation. Thromb Haemost. 2011;106:763-771.
11. Mantovani A, Sica A, Locati M. Macrophage polarization comes of age. Immunity. 2005;23:344-346.
12. Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, Law SK, Moestrup SK. Identification of the haemoglobin scavenger receptor. Nature. 2001;409:198-201.
13. Etzerodt A, Maniecki MB, Møller K, Møller HJ, Moestrup SK. Tumor necrosis factor α-converting enzyme (TACE/ADAM17) mediates ectodomain shedding of the scavenger receptor CD163. J Leukoc Biol. 2010;88:1201-1205.
14. Koths K, Taylor E, Halenbeck R, Casipit C, Wang A. Cloning and characterization of a human Mac-2-binding protein, a new member of the superfamily defined by the macrophage scavenger receptor cysteine-rich domain. J Biol Chem. 1993;268:14245-14249.
15. Dorrucci M, Ciccozzi M, Iacobelli S, Rezza G. Temporal trend in the level of 90K glycoprotein after HIV seroconversion among persons coinfected with hepatitis C virus. Infection. 2005;33:101-102.
16. Gröschel B, Braner JJ, Funk M, Linde R, Doerr HW, Cinatl J Jr, Iacobelli S. Elevated plasma levels of 90K (Mac-2 BP) immunostimulatory glycoprotein in HIV-1-infected children. J Clin Immunol. 2000;20:117-122.
17. Natoli C, Ortona L, Tamburrini E, Tinari N, Di Stefano P, D'Egidio M, Ghinelli F, Sighinolfi L, D'Ostilio N, Piazza M. Elevated serum levels of a 90,000 daltons tumor-associated antigen in cancer and in infection by human immunodeficiency virus (HIV). Anticancer Res. 1994;14(3B):1457-1460.
18. Epstein SE, Zhu J, Najafi AH, Burnett MS. Insights into the role of infection in atherogenesis and in plaque rupture. Circulation. 2009;119:3133-3141.
19. Tien PC, Schneider MF, Cole SR, Cohen MH, Glesby MJ, Lazar J, Young M, Mack W, Hodis HN, Kaplan RC. Association of hepatitis C virus and HIV infection with subclinical atherosclerosis in the women's interagency HIV study. AIDS. 2009;23:1781-1784.
20. Kaplan RC, Landay AL, Hodis HN, Gange SJ, Norris PJ, Young M, Anastos K, Tien PC, Xue X, Lazar J, Parrinello CM, Benning L, Tracy RP. Potential cardiovascular disease risk markers among HIV-infected women initiating antiretroviral treatment. J Acquir Immune Defic Syndr. 2012;60:359-368.
21. Cho HJ, Shashkin P, Gleissner CA, Dunson D, Jain N, Lee JK, Miller Y, Ley K. Induction of dendritic cell-like phenotype in macrophages during foam cell formation. Physiol Genomics. 2007;29:149-160.
22. Gruson D, Ko G. Galectins testing: new promises for the diagnosis and risk stratification of chronic diseases? Clin Biochem. 2012;45:719-726.
23. Ho JE, Liu C, Lyass A, Courchesne P, Pencina MJ, Vasan RS, Larson MG, Levy D. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol. 2012;60:1249-1256.
24. Lok DJ, Van Der Meer P, de la Porte PW, Lipsic E, Van Wijngaarden J, Hillege HL, van Veldhuisen DJ. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol. 2010;99:323-328.
25. van der Velde AR, Gullestad L, Ueland T, Aukrust P, Guo Y, Adourian A, Muntendam P, van Veldhuisen DJ, de Boer RA. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circ Heart Fail. 2013;6:219-226.
26. Novak R, Dabelic S, Dumic J. Galectin-1 and galectin-3 expression profiles in classically and alternatively activated human macrophages. Biochim Biophys Acta. 2012;1820:1383-1390.
27. Burdo TH, Lo J, Abbara S, Wei J, DeLelys ME, Preffer F, Rosenberg ES, Williams KC, Grinspoon S. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis. 2011;204:1227-1236.
28. Moreno JA, Dejouvencel T, Labreuche J, Smadja DM, Dussiot M, Martin-Ventura JL, Egido J, Gaussem P, Emmerich J, Michel JB, Blanco-Colio LM, Meilhac O. Peripheral artery disease is associated with a high CD163/TWEAK plasma ratio. Arterioscler Thromb Vasc Biol. 2010;30:1253-1262.
29. Urbonaviciene G, Martin-Ventura JL, Lindholt JS, Urbonavicius S, Moreno JA, Egido J, Blanco-Colio LM. Impact of soluble TWEAK and CD163/TWEAK ratio on long-term cardiovascular mortality in patients with peripheral arterial disease. Atherosclerosis. 2011;219:892-899.
30. Subramanian S, Tawakol A, Burdo TH, Abbara S, Wei J, Vijayakumar J, Corsini E, Abdelbaky A, Zanni MV, Hoffmann U, Williams KC, Lo J, Grinspoon SK. Arterial inflammation in patients with HIV. JAMA. 2012;308:379-386.
31. Knudsen A, Møller HJ, Katzenstein TL, Gerstoft J, Obel N, Kronborg G, Benfield T, Kjaer A, Lebech AM. Soluble CD163 does not predict first-time myocardial infarction in patients infected with human immunodeficiency virus: a nested case-control study. BMC Infect Dis. 2013;13:230.
32. Longenecker CT, Funderburg NT, Jiang Y, Debanne S, Storer N, Labbato DE, Lederman MM, McComsey GA. Markers of inflammation and CD8 T-cell activation, but not monocyte activation, are associated with subclinical carotid artery disease in HIV-infected individuals. HIV Med. 2013;14:385-390.
33. Reiner AP, Lange EM, Jenny NS, Chaves PH, Ellis J, Li J, Walston J, Lange LA, Cushman M, Tracy RP. Soluble CD14: genomewide association analysis and relationship to cardiovascular risk and mortality in older adults. Arterioscler Thromb Vasc Biol. 2013;33:158-164.
34. Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, Pedersen C, Ruxrungtham K, Lewin SR, Emery S, Neaton JD, Brenchley JM, Deeks SG, Sereti I, Douek DC; INSIGHT SMART Study Group. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011;203:780-790.
35. Amar J, Ruidavets JB, Bal Dit Sollier C, Bongard V, Boccalon H, Chamontin B, Drouet L, Ferrieres J. Soluble CD14 and aortic stiffness in a population-based study. J Hypertens. 2003;21:1869-1877.
36. Kelesidis T, Kendall MA, Yang OO, Hodis HN, Currier JS. Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection. J Infect Dis. 2012;206:1558-1567.
37. Paynter NP, Everett BM, Cook NR. Cardiovascular disease risk prediction in women: is there a role for novel biomarkers? Clin Chem. 2014;60:88-97.